Journal article
Viviana Volta, Amanda W Ernlund, Abhilash Gadi, Amanda Valeta-Magara, C. Parra, Preeyam S. Patel, R. Schneider
2020
2020
Semantic Scholar
DOI
Cite
Cite
APA
Click to copy
Volta, V., Ernlund, A. W., Gadi, A., Valeta-Magara, A., Parra, C., Patel, P. S., & Schneider, R. (2020). Abstract A26: mTOR inhibition promotes differentiation of human regulatory T cells via privileged mRNA translation.
Chicago/Turabian
Click to copy
Volta, Viviana, Amanda W Ernlund, Abhilash Gadi, Amanda Valeta-Magara, C. Parra, Preeyam S. Patel, and R. Schneider. “Abstract A26: MTOR Inhibition Promotes Differentiation of Human Regulatory T Cells via Privileged MRNA Translation” (2020).
MLA
Click to copy
Volta, Viviana, et al. Abstract A26: MTOR Inhibition Promotes Differentiation of Human Regulatory T Cells via Privileged MRNA Translation. 2020.
BibTeX Click to copy
@article{viviana2020a,
title = {Abstract A26: mTOR inhibition promotes differentiation of human regulatory T cells via privileged mRNA translation},
year = {2020},
author = {Volta, Viviana and Ernlund, Amanda W and Gadi, Abhilash and Valeta-Magara, Amanda and Parra, C. and Patel, Preeyam S. and Schneider, R.}
}
Abstract
Regulatory T cells (Tregs) maintain immune system homeostasis in the organism. In the tumor microenvironment, however, Tregs can hinder the antitumor immune response. Treg maturation in peripheral sites (pTregs) requires inhibition of protein kinase mTORC1, which paradoxically blocks mRNA translation. mTORC1 phosphorylates (inactivates) 4E-BP1, a negative regulator of the translation initiation factor eIF4E. When mTORC1 is active, 4E-BP1 is hyperphosphorylated and releases eIF4E, which can then bind the mRNA cap structure and promote eIF4F complex assembly and ribosome recruitment. Inhibition of mTORC1 results in hypo-phosphorylation (activation) of 4E-BP1, which then binds and sequesters eIF4E, preventing its interaction with the cap and ribosome association to the mRNA. Using human CD4+ T cells differentiated in vitro, we show that mTORC1 inhibition strongly impairs protein synthesis, yet with exposure to TGFbeta is essential to mediate iTreg differentiation and immune suppression activity. We found that TGFbeta reprograms the T-cell transcriptome, while mTORC1 inhibition reprograms the translatome (genome-wide translation signature), mediating Treg differentiation. Genome-wide transcription and translation profiling identified TGFbeta-upregulated mRNAs resistant to mTORC1 inhibition, in part due to their 59-untranslated regions, that induce Treg differentiation and immune-suppression activity. These include canonical pTreg fate-determining mRNAs FOXP3, CTLA-4, CD101 and CD103, among others. Inhibition of mTORC1 alone, or TGFbeta alone, induces iTregs with poor immune-suppression activity. Treg differentiation is therefore mediated by an mTORC1-independent privileged mRNA translation mechanism that converts activated CD4+ T cells to Tregs. These findings are quite relevant in the tumor microenvironment, where mTORC1-inhibiting conditions such as hypoxia and deprivation of nutrients and energy are present. Investigation of molecular targets acting in this mTORC1/eIF4E-independent translation of Treg mRNAs is ongoing. These targets could be drugged to selectively inhibit Treg differentiation in the tumor microenvironment, thus allowing effector cells to mount the response against cancer cells. Citation Format: Viviana Volta, Amanda Ernlund, Abhilash Gadi, Amanda Valeta-Magara, Columba de la Parra, Preeyam Patel, Robert J. Schneider. mTOR inhibition promotes differentiation of human regulatory T cells via privileged mRNA translation [abstract]. In: Proceedings of the AACR Special Conference on Targeting PI3K/mTOR Signaling; 2018 Nov 30-Dec 8; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Res 2020;18(10_Suppl):Abstract nr A26.
